"The majority of our patients with wet AMD eventually have bilateral disease and face a substantial treatment burden with frequent lifelong injections in both ... through a standardized subretinal ...
Oct. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal ... lifelong injections in both eyes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback